Loading cancer entity…
Loading cancer entity…
Clinical trials
1,008 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (169)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01396070 | Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level | completed | Phase 2 | 36 | Youn KimOTHER | 1 | Apr 5, 2017 | clinicaltrials |
| NCT01173887 | Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15 | completed | Phase 2 | 44 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Mar 30, 2017 | clinicaltrials |
| Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma |
| completed |
| Phase 2 |
| 28 |
| Kyowa Kirin Co., Ltd.INDUSTRY |
| 1 |
| Mar 29, 2017 |
| clinicaltrials |
| NCT01000285 | EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma(ATLL) | completed | Phase 1 / Phase 2 | 18 | Washington University School of MedicineOTHER | 1 | Mar 28, 2017 | clinicaltrials |
| NCT01181271 | Tandem Auto-Allo Transplant for Lymphoma | completed | Phase 2 | 42 | Massachusetts General HospitalOTHER | 1 | Mar 9, 2017 | clinicaltrials |
| NCT00684411 | Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma | completed | Phase 2 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 5, 2017 | clinicaltrials |
| NCT00611208 | A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL) | completed | Phase 2 | 32 | Virogen Biotechnology Inc.INDUSTRY | 1 | Nov 29, 2016 | clinicaltrials |
| NCT01421667 | A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma | completed | Phase 2 | 176 | Seagen Inc.INDUSTRY | 2 | Nov 28, 2016 | clinicaltrials |
| NCT00798096 | Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma | completed | Phase 2 | 18 | Rigel PharmaceuticalsINDUSTRY | 2 | Sep 19, 2016 | clinicaltrials |
| NCT01274533 | Lenalidomide in HTLV-1 Adult T-Cell Leukemia | completed | Phase 2 | 4 | Columbia UniversityOTHER | 1 | May 23, 2016 | clinicaltrials |
| NCT00322985 | A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma | completed | Phase 2 | 40 | AHS Cancer Control AlbertaOTHER | 1 | Mar 16, 2016 | clinicaltrials |
| NCT01466881 | Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma | completed | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 2 | Mar 10, 2016 | clinicaltrials |
| NCT00178841 | Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL | completed | Phase 2 | 4 | Vanderbilt UniversityOTHER | 1 | Feb 17, 2016 | clinicaltrials |
| NCT00131937 | Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma | completed | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Sep 3, 2015 | clinicaltrials |
| NCT00431912 | A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma | completed | Phase 2 | 25 | Valerio TherapeuticsINDUSTRY | 4 | Jul 8, 2015 | clinicaltrials |
| NCT00453427 | Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas(ACCAPELA) | completed | Phase 1 / Phase 2 | 20 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Jun 3, 2015 | clinicaltrials |
| NCT00003210 | Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease | completed | Phase 2 | 105 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00099593 | Immunization Against Tumor Cells in Sezary Syndrome | completed | Phase 2 | 17 | University of PittsburghOTHER | 1 | Mar 25, 2015 | clinicaltrials |
| NCT01198665 | RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas(RADCHOP) | completed | Phase 1 / Phase 2 | 46 | Samsung Medical CenterOTHER | 1 | Mar 3, 2015 | clinicaltrials |
| NCT01238159 | Concomitant Chemo-radiotherapy Followed by MIDLE Chemotherapy in Stage I/II Extranodal NK/T-cell Lymphoma | completed | Phase 2 | 30 | Samsung Medical CenterOTHER | 1 | Mar 3, 2015 | clinicaltrials |
| NCT00337987 | A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma | completed | Phase 2 | 49 | Yale UniversityOTHER | 1 | Feb 27, 2015 | clinicaltrials |
| NCT00079755 | Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma | completed | Phase 2 | 80 | Seagen Inc.INDUSTRY | 1 | Dec 18, 2014 | clinicaltrials |
| NCT00185965 | CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas | completed | Phase 1 / Phase 2 | 30 | Ronald LevyOTHER | 1 | Aug 1, 2014 | clinicaltrials |
| NCT00901147 | Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma | completed | Phase 2 | 25 | Singapore General HospitalOTHER | 3 | Jun 27, 2014 | clinicaltrials |
| NCT00117988 | 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00058019 | Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma | completed | Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT01280526 | A Study of Escalating Doses of Romidepsin in Association With CHOP in the Treatment of Peripheral T-Cell Lymphomas(Ro-CHOP) | completed | Phase 1 / Phase 2 | 37 | The Lymphoma Academic Research OrganisationOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT01806337 | CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma | completed | Phase 2 | 41 | University of GöttingenOTHER | 0 | Mar 7, 2013 | clinicaltrials |
| NCT00959686 | Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma(BENTLY) | completed | Phase 2 | 45 | French Innovative Leukemia OrganisationOTHER | 1 | Feb 12, 2013 | clinicaltrials |
| NCT00278382 | Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma | completed | Phase 2 | 33 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00016094 | S0108 Bevacizumab in Treating Patients With Non-Hodgkin's Lymphoma | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 29, 2013 | clinicaltrials |
| NCT00006473 | Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 2 | 72 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00005080 | 506U78 in Treating Patients With Lymphoma | completed | Phase 2 | 74 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00061048 | Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma | completed | Phase 2 | 29 | National Cancer Institute (NCI)NIH | 1 | Oct 31, 2012 | clinicaltrials |
| NCT00168064 | Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides | completed | Phase 2 | 260 | Yaupon TherapeuticsINDUSTRY | 1 | Oct 31, 2012 | clinicaltrials |
| NCT00535470 | An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides | completed | Phase 2 | 100 | Yaupon TherapeuticsINDUSTRY | 1 | Aug 9, 2012 | clinicaltrials |
| NCT00930605 | The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL)(C+CHOP/ESHAP) | completed | Phase 2 | 16 | King Chulalongkorn Memorial HospitalOTHER | 1 | Oct 6, 2011 | clinicaltrials |
| NCT00791947 | A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCT | completed | Phase 2 | 166 | University of AarhusOTHER | 3 | Sep 8, 2011 | clinicaltrials |
| NCT01177371 | High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma | completed | Phase 2 | 13 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 9, 2010 | clinicaltrials |
| NCT00418535 | Clinical Study of Chemoradiation Followed by VIPD in Nasal Natural Killer (NK)/T-cell Lymphoma | completed | Phase 2 | — | Samsung Medical CenterOTHER | 1 | Oct 21, 2009 | clinicaltrials |
| NCT00374699 | Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas | completed | Phase 1 / Phase 2 | 55 | Samsung Medical CenterOTHER | 1 | Oct 14, 2009 | clinicaltrials |
| NCT00043368 | PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909) | completed | Phase 2 | 31 | PfizerINDUSTRY | 2 | Mar 12, 2009 | clinicaltrials |
| NCT00306969 | Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cutaneous T-Cell Lymphoma | completed | Phase 1 / Phase 2 | 18 | Boston UniversityOTHER | 1 | Mar 27, 2006 | clinicaltrials |
Data updated 23 days agoSource updated Apr 5, 2017source: clinicaltrials